Cyclacel Pharmaceuticals is a biopharmaceutical company focused on developing oral therapies that target the various cell cycle control phases to treat cancer and other serious diseases. Sapacitabine, the company’s most advanced oral product candidate, is the subject of SEAMLESS – a Phase 3 clinical trial being conducted under an SPA with the FDA. The company’s pipeline also includes seliciclib and CYC065, both in various stages of development. For more information, visit the company’s Web site at www.cyclacel.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: